Boehringer
Boehringer signs antibody myeloma R&D deal
May 10, 2010Research and Development Boehringer, Cancer, Micromet, myeloma
Boehringer Ingelheim and US biotech company Micromet are to research and develop a new BiTE antibody to treat multiple myeloma. …
Boehringer enters the venture capital business
March 31, 2010Research and Development, Sales and Marketing Boehringer, funding, venture capital
Boehringer Ingelheim is to tap into commercial opportunities in emerging technology by launching its own venture capital business. The Boehringer …
Boehringer targets ‘genome guardian’ protein for cancer collaboration
January 19, 2010Research and Development Boehringer, Cancer, Priaxon, genome
Boehringer Ingelheim has signed a worldwide deal with Munich-based pharma firm Priaxon to find novel treatments for cancer. The firms …
Boehringer’s ovarian cancer drug enters phase III
December 18, 2009Research and Development, Sales and Marketing Boehringer, Cancer, ovarian
Boehringer Ingelheim has started a new phase III trial for its investigational cancer drug BIBF 1120. The LUME-Ovar-1 programme will …
Digital Pharma: A Year in Digital (5/5)
December 16, 2009Medical Communications 2009, Boehringer, digi, digital pharma, year in review
Favourite use of digital (pharma)• Microsoft’s future of healthcare video. It’s their vision of the possibilities that I fell in …
Boehringer prepares for diabetes launch
December 3, 2009Medical Communications Boehringer, DPP-4, diabetes
Boehringer Ingelheim has hired the London arm of international PR agency Weber Shandwick to handle the UK launch of its …
Pradaxa data boosts Boehringer
September 1, 2009Research and Development, Sales and Marketing Boehringer, Pradaxa
Boehringer Ingelheim has unveiled new positive data for its blood-thinner Pradaxa, showing it reduces the risk of stroke compared to …
Boehringer’s lung cancer candidate enters phase III
August 5, 2009Research and Development, Sales and Marketing Boehringer, Cancer
Boehringer Ingelheim is to enter phase III studies with a candidate to treat a subset of patients with non-small cell …
Boehringer collaboration targets Alzheimer’s
June 18, 2009Research and Development, Sales and Marketing Boehringer, CNS
Boehringer Ingelheim and Pennsylvania-based Vitae Pharmaceuticals have signed a global agreement to develop novel treatments for Alzheimer's. The disease currently …
Boehringer signs diabetes and obesity deal
May 14, 2009Research and Development, Sales and Marketing Boehringer
Boehringer Ingelheim has signed a deal with German biopharma firm DeveloGen to research and develop treatments for diabetes and obesity. …
Boehringer Ingelheim takes the lead on Twitter
April 8, 2009Medical Communications, Sales and Marketing Boehringer, Twitter, new media, social networking
The explosion in the popularity of Twitter is the latest buzz in online social networking, but most pharma companies are …
Boehringer’s cancer drug enters phase III
November 21, 2008Sales and Marketing Boehringer, Cancer
Boehringer Ingelheim's new lung cancer drug Vargatef has entered phase III trials.The drug is part of the manufacturer's burgeoning oncology …
Spiriva partners defend drug’s safety
October 2, 2008Sales and Marketing Boehringer, COPD, Spiriva, resp
Boehringer Ingelheim and Pfizer have released new data on Spiriva to defend the safety record of the chronic obstructive pulmonary …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
